Taste and nutrition company, Kerry, and c-LEcta, a biotech company in enzyme engineering and bioprocess development, will jointly market DENARASE® products in Asia.
The DENARASE® product family was launched in 2012 and applied in hundreds of clinical and commercial production processes for gene/cell therapies and vaccines.
Combining Kerry and c-LEcta’s expertise in the biopharma and pharmaceutical sectors, the partnership will see DENARASE® reach more customers in Asia and globally while accelerating innovation opportunities in novel therapies and vaccines.
Barbara Morgan, Global VP Pharma of Kerry, said: “We are excited to support and enable the global reach of the DENERASE® products by leveraging our dedicated Kerry pharma team and routes to market. Working closely with c-LEcta, we are positioned to collaborate directly with our customers by providing them with greater access to innovative technologies to support market needs and we look forward to continuing to expand this portfolio.”
Dr Marc Struhalla, CEO of c-LEcta, added: “We are delighted that, through Kerry’s global presence and long-standing expertise, DENARASE® will now be available to a wider customer base and have access to attractive new market opportunities. This step represents significant added value for our customers through expanded local availability of our DENARASE® products. We are looking forward to further accelerate the support for our customers and we are proud to help them develop novel therapies and vaccines.”
Kerry acquired a majority interest in c-LEcta in 2022, which operates as a stand-alone company while leveraging the breadth and depth of Kerry’s global application and commercial capabilities.